Title:
A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
Phase:
I/II
Contact:
Katharina Hilse / Kontaktperson
Email-Address:
Katharina.Hilse@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. Guy Ungerechts
Registration:
Keine Registernummer angegeben.
EudraCT-Number:
Siehe EU klinisches Studienregister
2020-003996-16